Prescribing Information can be found at the bottom of this page.
PROVEN EFFICACY IN ONE OF THE LARGEST CLINICAL TRIALS IN AK1,2
Two identical, pivotal double-bind, randomised, vehicle-controlled, phase III clinical study program
702 adult patients with AK on the face or scalp
>80% male patients; average age: 70 years
96% of patients had Fitzpatrick skin type I, II or III
4-8 clinically typical, visible, and discrete AK lesions in a contiguous area of 25 cm2
References
1. KLISYRI® PI. KLISYRI® SmPC. Almirall. 2. Blauvelt A, et al. Phase 3 Tirbanibulin for Actinic Keratosis Group. Phase 3 Trials of Tirbanibulin Ointment for Actinic Keratosis. N Engl J Med. 2021;384(6):512-520. 3. Blauvelt A, et al. Phase 3 Tirbanibulin for Actinic Keratosis Group. Phase 3 Trials of Tirbanibulin Ointment for Actinic Keratosis. N Engl J Med. 2021;384(6):512-520. Supplementary appendix.